MX2023006366A - Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. - Google Patents

Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.

Info

Publication number
MX2023006366A
MX2023006366A MX2023006366A MX2023006366A MX2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A MX 2023006366 A MX2023006366 A MX 2023006366A
Authority
MX
Mexico
Prior art keywords
extended release
dosing regimens
injectable formulations
regimens associated
release paliperidone
Prior art date
Application number
MX2023006366A
Other languages
English (en)
Inventor
Srihari Gopal
Raja Venkatasubramanian
Huybrecht T''jollyn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023006366A publication Critical patent/MX2023006366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar pacientes con formulaciones de palmitato de paliperidona inyectable de acción prolongada.
MX2023006366A 2020-11-30 2021-05-07 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. MX2023006366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
MX2023006366A true MX2023006366A (es) 2023-08-07

Family

ID=75888043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006366A MX2023006366A (es) 2020-11-30 2021-05-07 Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.

Country Status (18)

Country Link
US (2) US11304951B1 (es)
EP (2) EP4025188B1 (es)
JP (1) JP2023552329A (es)
KR (1) KR20230116013A (es)
CN (1) CN116583270A (es)
AU (1) AU2021386450B2 (es)
CA (1) CA3203566A1 (es)
DK (1) DK4025188T3 (es)
FI (1) FI4025188T3 (es)
HR (1) HRP20240074T1 (es)
IL (1) IL303253A (es)
LT (1) LT4025188T (es)
MX (1) MX2023006366A (es)
PT (1) PT4025188T (es)
RS (1) RS65178B1 (es)
SI (1) SI4025188T1 (es)
TW (1) TW202222319A (es)
WO (1) WO2022111859A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4005555B1 (en) 2020-11-30 2024-05-15 Janssen Pharmaceutica NV Methods for ensuring resuspension of paliperidone palmitate formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
CN101932327A (zh) 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
UA118732C2 (uk) 2015-04-07 2019-02-25 Янссен Фармасьютикалз, Інк. Схема введення пропущених доз естерів паліперидону тривалої дії для ін'єкційного застосування
BR112020011614A2 (pt) * 2017-12-14 2020-12-08 SpecGx LLC Processo de moagem de uma etapa para preparar ésteres de paliperidona micronizada

Also Published As

Publication number Publication date
EP4356966A2 (en) 2024-04-24
FI4025188T3 (fi) 2024-02-21
PT4025188T (pt) 2024-02-29
US20220249495A1 (en) 2022-08-11
LT4025188T (lt) 2024-03-12
DK4025188T3 (da) 2024-03-04
RS65178B1 (sr) 2024-03-29
US11304951B1 (en) 2022-04-19
EP4025188A1 (en) 2022-07-13
KR20230116013A (ko) 2023-08-03
CA3203566A1 (en) 2022-06-02
HRP20240074T1 (hr) 2024-03-29
EP4025188B1 (en) 2024-01-10
IL303253A (en) 2023-07-01
SI4025188T1 (sl) 2024-03-29
TW202222319A (zh) 2022-06-16
JP2023552329A (ja) 2023-12-15
WO2022111859A1 (en) 2022-06-02
AU2021386450B2 (en) 2024-03-21
CN116583270A (zh) 2023-08-11
AU2021386450A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
CL2019001292A1 (es) Nuevos derivados de quinolina.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
CL2020000301A1 (es) Nuevos derivados de quinolina.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
CO6300949A2 (es) Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
BR112017000470A2 (pt) composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
MX2023006370A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
MX2018004664A (es) Antagonistas de ep4.
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MY194576A (en) Methods for the treatment of recurrent glioblastoma (rgbm)
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
MX2023006368A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2023006366A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.